The mechanism of botulinum A on Raynaud syndrome

Background: Botulinum neurotoxin type A (BoNT/A) is emerging as a treatment modality for Raynaud’s phenomenon (RP). However, the mechanism of the role of BoNT/A in antagonizing the constriction of arteriola in RP remains unclear.

Materials and methods: We tested the constriction of arteriola diameter and the distribution of adrenergic receptors on the rat cremaster module. Moreover, we measured the secretion of norepinephrine (NE), protein level changes and related receptors on cultured rat superior cervical ganglia neurons (SCGNs), a model of sympathetic neuron.

Results: Based on our results, the inhibition of arteriola vasoconstriction was increased with increasing doses of BoNT/A. BoNT/A, prazosin, and BQ123 treatment can result in significant inhibition of arteriola vasoconstriction with the same electrical stimulation. The inhibition effect of prazosin was equivalent to BoNT/A, while BQ123 has a synergistic effect with BoNT/A. After treating SCGNs using BoNT/A for 30 min, the decrease in fluorescence intensity of FM1-43 slowed down which was correlated with the doses of BoNT/A. Furthermore, release of NE in the supernatant was significantly decreased as measured by enzyme-linked immunosorbent assay, 24 h after a high dose of BoNT/A (25 µ/mL). Cleaved-SNAP-25 was detected by Western blotting 24 h following BoNT/A (50 µ/mL) treatment. Moreover, receptor SV2C, GM1, and FGFR3 were detected on sympathetic neurons, similarly to cholinergic neurons.

Conclusion: Our study showed that BoNT/A could significantly inhibit electrical stimulation-induced arteriola vasoconstriction through the sympathetic pathway. The mechanism was similar to the cholinergic one, in which the vesicle release of sympathetic neurons could be inhibited by cleavage of SNAP-25. The end result was blocked vesicle fusion with the presynaptic membrane after BoNT/A treatment, inhibiting the release of the NE.

Keywords: botulinum neurotoxin type A, Raynaud’s phenomenon, α-adrenoceptor, arteriola diameter constriction rate, SNAP-25, SV2C, GM1, FGFR3, sympathetic neuron, vesicle cycle

Introduction

Raynaud’s phenomenon (RP) is a disease in which the digits turn white, then blue accompanied with pain or paresthesia under cold or abnormal emotional condition. These conditions exaggerate a vasospastic response which may participate in the development of the disease. The morbidity of RP is about 3%-5% and is closely related to weather and geographical environment. It has been defined as a clinical disease for about 150 years, however its etiology and pathogenesis remain unknown. Currently, accumulating evidence suggested that upregulated vascular smooth muscle α2C adrenergic receptor may play an important role in RP through inducing hyperfunction of the sympathetic nervous system and causing vasoconstriction. Up to now, traditional therapy for RP includes pharmacologic drugs and surgery. The curative effect of drugs is unsatisfactory, and sympathetic trunk transection can cause
complications, including compensatory body hydrosis and Horner syndrome. Therefore, a novel replacement therapy is urgently needed.5–8

Botulinum neurotoxin type A (BoNT/A) was first applied in treatment of RP in 2004. Blood flow in the injection site was improved notably by this approach.9 Subsequently, several other clinical trials have also proved that BoNT/A can relieve digital arterial spasm, increase blood flow, promote ulcer healing, and alleviate pain without complications.10–14 Our colleagues reported that the blood flow of a patient’s midfinger increased to 40 cm/s, which could not be detected before BoNT/A injection.15 Furthermore, this kind of therapy has less adverse reactions. As a proposed new therapy, BoNT/A injection has become the hope for refractory RP.

Up to now, the role of BoNT/A in blocking the release of acetylcholine has been reported.23 However, the mechanism of the role of BoNT/A in antagonizing the constriction of arteriolar RP is still under study. To clarify the hypothesis that the vasodilatation caused by BoNT/A is due to the blockage of a norepinephrine-mediated sympathetic pathway, we established an electrical stimulation-induced rat cremaster arteriole contraction model. This model allows comparison of the vasodilatation effect between prazosin, Yohimbine, and BQ-123 with BoNT/A. Furthermore, it allows us to investigate the mechanism of BoNT/A on arteriole vasodilation. To define the mechanism, we also clarified the type and distribution of norepinephrine receptors on the cremaster arteriole. Moreover, we cultivated primary sympathetic neurons from superior cervical ganglion neurons (SCGNs) to study the effect of BoNT/A on the sympathetic nerve system and tried to explore its mechanism through the protein level. Then, we also examined whether GM1 (a subtype of ganglioside), SV2C, and FGFR3 existed in cholinergic neurons also presented in the sympathetic nervous system.

Materials and methods

This study was approved by the Institutional Animal Care and Use Committee of Tongji Hospital. All portions of the protocol were performed in accordance with the institutional guidelines. The animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institution of Health and the Policy of Animal Care and Use Committee of Tongji University.

Cremaster arteriole vasoconstriction model establishment

A validated rat cremaster model was used to study the inhibition of BoNT/A on arteriole vasoconstriction.16,17 72 hours before anesthesia, male Sprague Dawley rats (100±10 g; n=96) were injected with BoNT/A or isopycnic 0.9% saline in the proximal and distal rat cremaster muscle. All animals were next anesthetized with 3% pentobarbital (intraperitoneal injection, 30 mg/kg body weight) (Sigma-Aldrich Co., St Louis, MO, USA). They were placed supine on a stage equipped with a reservoir to perfuse the cremaster muscle. After removal of the testicle, the cremaster muscle was exposed, and then stretched over an adjustable, raised pedestal surrounded by a 2-piece reservoir. Regional perfusion was kept with perfusate by the thermostatic circulator at 37°C. Next, we delivered a constant voltage of 30 V with varying frequency (5, 10, 16, 20, and 25 Hz) or a constant frequency of 16 Hz with varying voltage (10, 20, 30, and 40 V). Each electric-impulse stimulation was delivered for 5 s every 5 min to find the ideal vasoconstriction model.

Drug treatment in the vasoconstriction model

A recirculating tissue bath, mimicking physiologic conditions, provided a method of local delivery of drugs at reasonable concentrations. The bath and pump reservoir were filled with buffered modified Krebs solution at room temperature (24°C), recirculating with a peristaltic pump and a pressure servo control (Living Systems Instrumentation, Burlington, VT, USA). All drug solutions were added directly to the tissue bath. Lyophilized BoNT/A (Botox, 100 U; Allergan, Inc., Irvine, CA, USA) was freshly dissolved with 1 mL of 0.9% saline. Five different doses of BoNT/A were chosen to study: 0.5 U/kg (group 9), 1.5 U/kg (group 10), 5 U/kg (groups 5–8), 15 U/kg (group 11), 50 U/kg (group 12), and 0.9% saline (groups 1–4). The 15 U/kg dose was chosen as the optimum concentration. Vessel diameters were measured 72 hours after toxin addition, and every 5 min thereafter, for a total of 20 min. The concentrations of prazosin, Yohimbine, and BQ-123 were chosen based on clinical doses and reviewed from previously published reports.25,44,45 Krebs solution, prazosin (0.1 µM, selective postsynaptic alpha 1 receptor blocker), Yohimbine (1 µM, selective blocker of presynaptic alpha 2 receptor, promotes the release of norepinephrine), and BQ-123 (1 µM, endothelin A receptor antagonist) were freshly dissolved with 1.0 mL of 0.9% saline, and then added directly to the tissue bath.

Arteriole diameter measurement

Arteriole diameter measurement was obtained with live video microscopy. The vessel’s internal diameters were measured from wall to wall by a video dimension micrometer. The video micrometer was calibrated on-screen with a...
stage micrometer scale before the start of each experiment. To eliminate the confounding effect of vascular response to the altered metabolic rate by toxin-mediated muscle paralysis, gallamine triiodide (gallamine, 0.17 mM; Sigma-Aldrich Co.), an acetylcholine receptor antagonist, was added into the perfusate for 10 min. Although gallamine did not cause significant changes in vessel diameter, baseline measurement was done after the addition of gallamine. The electrical stimulation-induced cremaster arteriole vasoconstriction model (30 V, 16 Hz, 5 s) was used to mimic the arteriole vasoconstriction with intervals of 5 min. The diameters of cremaster arteriole were recorded and the arteriole diameter constriction rate was established by the following equation: arteriole diameter shrinkage rate = [diameter of arteriole before electrical stimulation – diameter of arteriole after electrical stimulation]/diameter of arteriole before electrical stimulation ×100%.

Tissue preparation and immunofluorescence
Cremaster arteriole was prepared from Sprague Dawley rats, ages 2–4 months. Tissue sections were incubated with permeabilizing/blocking solution (0.5% Triton X-100 and 10% goat serum in PBS) for 24–48 h at 4°C. The sections were then incubated with α1-AR (1:1,000; Thermo Fisher Scientific, Waltham, MA, USA), α2A-AR (1:1,000; Santa Cruz Biotechnology Inc., Dallas, TX, USA), α2B-AR (1:1,000; Santa Cruz Biotechnology Inc.), and α2c-AR (1:1,000; Santa Cruz Biotechnology Inc.) antibodies, which were dissolved in PBS. Control experiments were done using PBS without antibodies. Samples were next washed with PBS 3 times, and incubated with donkey anti-rabbit biotin (1:1,000; Jackson Immunoresearch Laboratories, West Grove, OR, USA). The experiment was conducted under static conditions. The dye was dissolved in ice-cold Hank’s balanced salt solution, and 5-fluorouracil and uridine. The medium was replaced once every 2 days as needed. After establishing that the cells (cultured for 3 days) were SCGNs through an immunofluorescence assay, mature cells (cultured for 7 days) were exposed to solutions with different concentrations of BoNT/A. BoNT/A was dissolved in stimulation buffer containing 56 mM KCl, 82 mM NaCl, 2 mM CaCl2, and 1 mM MgCl2, to different concentration (5 U/mL, 10 U/mL, 25 U/mL and 50 U/mL).

Immunofluorescence labeling of sympathetic neurons
SCGNs which were grown for 3 days on glass dishes were rinsed three times with PBS and then fixed with intracellular fixation buffer for 20 min, followed by permeabilization for 10 min. After blocking with 1% fetal bovine serum in PBS, the cells were then incubated with a monoclonal anti-mouse antibody against neurofilament-200 (N52) and a polyclonal anti-rabbit antibody against tyrosine hydroxylase (Abcam) diluted to 200× in blocking solution at 4°C overnight.

In experiment 4, the cells were incubated with polyclonal anti-rabbit antibody against tyrosine hydroxylase (Abcam) and monoclonal anti-mouse antibody against SNAP-25 (SMI-81; Bioregen, San Diego, CA, USA) diluted to 200× in blocking solution at 4°C overnight. In experiment 5, the cells were incubated with polyclonal anti-rabbit antibody against SV2C (Abcam), polyclonal anti-rabbit antibody against ganglioside GM1 (Abcam), and monoclonal anti-rabbit antibody against FGF2 (Abcam). After the cells were incubated with PBS 3 times, they were exposed to anti-mouse IgG H&L (tetramethylrhodamine isothiocyanate [TRITC]) and anti-rabbit Alexa Fluor488 (Abcam) for 40 min. Images were captured on a Fluorescence Inverse Microscope Nikon ECLIPSE80i (Nikon corporation, Tokyo, USA).

Loading and unloading of FM1-43
SCGNs grown for 7 days in plastic-bottomed dishes and optimized for confocal laser scanning microscopy were exposed to fluorescent styryl dye FM1-43 (Molecular Probes, Eugene, OR, USA). The experiment was conducted under static conditions. The dye was dissolved in ice-cold Hank’s balanced salt solution to produce a working staining solution. The staining solution was added into the plastic-bottomed dish with SCGNs grown on it for 5 min. This ensures quick plasma membrane staining. After taking photos, the staining solution was removed, and the stimulation staining solutions with different concentrations of BoNT/A were added to the cultured cells.
Photos were captured continuously on a confocal microscopy (model TCS SP5; Leica Microsystems, Wetzlar, Germany) for 30 min. We also interfered with the cells with stimulation staining solutions containing different concentrations of BoNT/A for 1 h. After taking photos, the solutions were removed, and cells were washed with Hank’s balanced salt solution for 3 times. The cells were then stimulated again to capture the changes of vesicle circulation after interfering.

**Norepinephrine quantitative analyses**

NE was collected from the cell supernatant and stored at −80°C. Enzyme-linked immunosorbent assay (ELISA) kits (Xinqidi Biological Technology Ltd, Wuhan, China) were used to determine the concentrations of NE under various conditions. The sensitivity limits of NE were 5 pg/mL.

**Western blot analyses**

Cultured SCGNs were washed with PBS. Cells were lysed by radioimmunoprecipitation assay for 10 s on ice, and whole cell lysates were collected and centrifuged (12,000 g; 10 min at 4°C). Samples were incubated for 5 min at 95°C with 5× loading buffer. Next, the proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis on 10% Bis–Tris gels and then transferred to polyvinylidene fluoride membranes. Membranes were incubated in blocking buffer (Tris-buffered saline with Tween 20 [TBST] and 5% skimmed milk powder) for 1 h, followed by incubation with the primary antibodies. The following primary antibodies were used: β-actin (D6A8) rabbit mAb (Cell Signaling Technology, Danvers, MA, USA), 1:1,000, overnight; and purified anti-SNAP-25 antibody (SMI-81; Biolegend, San Diego, CA, USA), 1:1,000, overnight at 4°C. The appropriate secondary antibodies, coupled to horseradish peroxidase, were added at a dilution of 1:1,000 for 1 h at room temperature. Proteins were detected using the Immobilon Western Chemiluminescent HRP Substrate (EMD Millipore, Billerica, MA, USA) on an Alphalmager HP (Protein Simple, San Jose, CA, USA). Quantification of Western blots was carried out using the gel analysis tool of Alpha View SA (Protein Simple).

**Statistics**

All data in this research were normally distributed and analyzed by GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS19.0 software (IBM Corporation, Armonk, NY, USA). The data were expressed as mean±standard error of the mean (SEM) using one-way analysis of variance, Fisher’s least significant difference, and Student’s t-test. A two-tailed $p<0.05$ was considered to be statistically significant.

**Results**

The effect of different drugs on arteriole constriction

A vasoconstriction model was established and accepted as ideal with the following parameters: electric impulse stimulation for 5 s, voltage of 30 V, and frequency of 16 Hz. To establish the adrenergic and endothelin component of the observed response to BoNT/A, prazosin (alpha 1 receptor blocker), Yohimbine (alpha 2 receptor blocker), and BQ-123 (endothelin A receptor antagonist) were selected. Similarly-sized vessels were prepared to study the constriction effect of arterioles under different drugs. Application of Kreb’s solution and gallamine resulted in no change of cremaster arteriole diameter and arteriole diameter constriction rate ($p>0.05$), and the average arteriole diameter was 59.71±2 µm.

In the absence of pretreatment with BoNT/A, the effects of prazosin (0.1 µM), Yohimbine (1 µM), BQ-123 (1 µM), and BoNT/A (5 U/kg) on the arteriole diameter constriction rate are shown in Figure 1. When compared to Krebs treatment (15.43±2.79), prazosin (6.71±1.04), BQ-123 (7.48±1.06), and BoNT/A (6.51±1.02) can effectively decrease the arteriole diameter constriction rate. The effects of prazosin and BoNT/A treatments are equivalent, while Yohimbine (15.31±0.91) showed no significant effect on arteriole vasoconstriction.

The effect of BoNT/A on arteriole vasodilation is dose dependent

Application of BoNT/A resulted in significant arteriolar vasodilation. After BoNT/A treatment, the arteriole diameters

---

**Figure 1** The effects of prazosin (0.1 µM), Yohimbine (1 µM), BQ-123 (1 µM), and BoNT/A (5 U/kg) on arteriole diameter constriction rate.

**Notes:** *p<0.05 vs Krebs solution. Data expressed as mean±SD from five independent experiments. Validated rat cremaster model treated with buffered modified Krebs solution regarded as control.

**Abbreviation:** BoNT/A, botulinum neurotoxin type A.
The mechanism of botulinum A on Raynaud syndrome

were significantly changed when compared to each control treatment (denatured BoNT/A and saline groups, \( p<0.01 \)) (Figure 2). Moreover, there was a dose-dependent effect of BoNT/A on arteriole vasodilation. When compared with the saline group, the doses of 0.5 U/kg, 1.5 U/kg, and 5 U/kg had similar roles on arteriole vasodilation, and produced a significantly dilatory effect arteriole. There was no significant difference between these groups. When the concentration increased gradually, the 15 U/kg and 50 U/kg groups had greater effect on the inhibition of arteriole contraction. However, there was no difference between the 15 U/kg group and the 50 U/kg group.

The interaction effect between BoNT/A and other drugs

Pretreatment experiments with BoNT/A (5 U/kg) and the functional consequences of prazosin (0.1 \( \mu \)M), Yohimbine (1 \( \mu \)M), and BQ-123 (1 \( \mu \)M) treatments on arteriole diameter constriction rate are shown in Figure 3. When compared to Krebs treatment alone (6.51±1.02), BQ-123 (4.11±0.63, \( p<0.01 \)) treatment has a synergistic effect on the arteriole diameter constriction rate with BoNT/A (5 U/kg) at pretreatment administration. However, prazosin (6.54±1.11, \( p>0.05 \)) and Yohimbine (6.67±1.12, \( p>0.05 \)) treatments did not have an interaction effect with BoNT/A.

Identification of primary sympathetic neurons

To confirm the purity of cells, SCGNs cultured for 3 days were immunostained with NF-200 antibody and TH antibody. As shown in Figure 5, immunofluorescence analyses showed that the cells cultured in our study were positive for both NF-200 and TH antibodies. This finding proves that the cells assessed were sympathetic neurons with catecholamine secreting function. Moreover, the primary sympathetic neurons had high purity.

The inhibition of vesicle cycle by BoNT/A

To investigate the vesicle cycle in sympathetic neurons and the effect that BoNT/A on it, FM1-43, a membrane dye, was used in this study. Exposure of sympathetic neurons to FM1-43 for 5 min in the absence of depolarization stimuli resulted in small fluorescent spots in various sizes on the cell bodies (Figure 6A). Direct bath application of 56 mM K+ increased the intensity of FM1-43-labeled puncta on the cell instantly when compared to the control. The intensity of FM dye-labeled puncta gradually decreased during the 30-min observation time (Figure 6A, control). This finding suggests an increase in endocytosis and exocytosis in the presence of an external stimuli. Subsequent washout of the

---

Figure 2 BoNT/A led to a dose-dependent and time-dependent vasodilatory response.

Notes: \( * p<0.05, \) 0.5 U/kg, 1.5 U/kg, and 5 U/kg vs control; \( * * p<0.001, \) 15 U/kg and 50 U/kg vs control.

Abbreviations: BoNT/A, botulinum neurotoxin type A; NS, normal saline.

Figure 3 Pretreatment with BoNT/A (5 U/kg) and the functional consequences of prazosin (0.1 \( \mu \)M), Yohimbine (1 \( \mu \)M), and BQ-123 (1 \( \mu \)M) treatments on arteriole diameter constriction rate.

Notes: \( * p<0.05 \) vs Krebs solution. Data expressed as mean±SD from five independent experiments. Validated rat cremaster model treated with buffered modified Krebs solution and BoNT/A regarded as control.

Abbreviation: BoNT/A, botulinum neurotoxin type A.

---

Distribution of \( \alpha_1 \) and \( \alpha_2 \) receptors on the rat cremaster arteriole

The immunofluorescence microscope was used to analyze the distribution of adrenergic receptors on the rat cremaster arteriole. In our study, we found that \( \alpha_1 \) and \( \alpha_2A \) receptors were coexpressed on rat cremaster arteriole. However, \( \alpha_2B \) and \( \alpha_2C \) receptors were absent (Figure 4).

---

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 19-Dec-2018
For personal use only.
Powered by TCPDF (www.tcpdf.org)
dye reduced the intensity of puncta to a lower level. The changes of laboratory dye intensity were examined in the presence of different doses of BoNT/A (5 U/mL, 10 U/mL, and 25 U/mL) for 30 min. The intensity of FM dye-labeled puncta decreased gradually with increasing reaction time. BoNT/A infusion to the cells delayed the intensity of puncta size in the cell stomata. Furthermore, as the dose of BoNT/A increased, the rate of dye fading also decreased. There was no significant difference in the change of the intensity of FM dye-labeled puncta per minute between the 10 U/mL BoNT/A group treatment and the 25 U/mL BoNT/A group treatment ($p > 0.05$).

The vesicle cycle of cultured sympathetic neurons after BoNT/A interfering

To further test the effect of BoNT/A on sympathetic neurons, we treated the targeted cells with different doses of BoNT/A (0 U/mL, 5 U/mL, 10 U/mL, and 25 U/mL) for 1 h. The cells were then stained with FM1-43 in bath application containing 56 mM K$^+$. The high K$^+$ induced high fluorescence intensity in different doses of BoNT/A-treated samples. Furthermore, the fluorescence intensity was enhanced rapidly and remarkably ($p < 0.05$) after the infusion of 56 mM K$^+$ in the control (Figure 6B) and the 5 U/mL treated group (Figure 6B, 5 U/mL). A dose increment of BoNT/A decreased the fluorescence intensity after high K$^+$ infusion. However, the enhancement of fluorescence intensity was not significant ($p > 0.05$) in the 10 U/mL and 25 U/mL BoNT/A-treated groups (Figure 6B, 10 U/mL and 25 U/mL).

Figure 4 Distribution of α1 and α2 receptors on the rat cremaster arteriole.
Notes: (A) α1 and α2A receptors were coexpressed on rat cremaster arteriole (white arrow). (B) α2B receptors were not found on rat cremaster arteriole. (C) α2C receptors were not found on rat cremaster arteriole. The white arrows indicate α1 and α2A receptors on the rat cremaster arteriole (magnification ×200, bar=100 µm).
Abbreviation: DAPI, 4′,6-diamidino-2-phenylindole.

Figure 5 Identification of primary sympathetic neurons by immunofluorescence.
Notes: The cells derived from SCGs of newborn (1–3 days) rats were TH (green) and NF-200 (red) immunopositive. Overlaid images showed that NF-200 (red), TH, and DAPI (blue) completely overlapped (magnification ×200, bar=100 µm).
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; NF-200, neurofilament-200; TH, tyrosine hydroxylase.
The mechanism of botulinum A on Raynaud syndrome

NE release decreased after BoNT/A treatment

Cell supernatants were collected on day 3, 5, and 7 before BoNT/A treatment and on day 8 after 24 h BoNT/A treatment. As shown in Figure 7, the concentration of NE decreased remarkably in the BoNT/A-treated group. Moreover, the concentration of NE declined from 148.965±5.192 (mean±SEM) to 78.708±0.805 pg/mL in the 25 U/mL treated group and from 131.441±3.720 to 68.460±3.130 pg/mL in the 50 U/mL treated group (*p<0.01 for both). These in vitro results indicate that the ability of sympathetic neurons to release NE transmitter was suppressed by BoNT/A.

The target protein of BoNT/A in sympathetic neurons is SNAP-25

To confirm that the release of NA in sympathetic neurons was also related to SNAP-25, we studied the distribution of

Figure 6 The inhibition of vesicle cycle by BoNT/A.
Notes: (A) The vesicle cycle of sympathetic neuron after injection of BoNT/A with different doses in 30 min. FM1-43 together with SB and 0 U/mL, 5 U/mL, 10 U/mL, 25 U/mL BoNT/A were added in different groups. Leica TCS SPS LSCM was used to observe the changes of fluorescence intensity in 30 min. Live-cell staining images of sympathetic cells labeled with FM1-43(red) in 0.15,30 min are shown. The chart showed the changes of fluorescence intensity at different time points within 30 min(magnification: 400×, bar: 100 µm). (B) The effect of different doses of BoNT/A on the vesicle cycle after 1 hours of injection. The charts showed changes of fluorescence intensity when stimulated with SB after 1 hour of BoNT/A (0 U/mL, 5 U/mL, 10 U/mL, 25 U/mL) intervention in each group. *p<0.05.
Abbreviations: BoNT/A, botulinum neurotoxin type A; Ctrl, control; SB, stimulation buffer.

Figure 7 NA release decreased after BoNT/A treatment.
Notes: *p<0.05, the concentration of NE decreased remarkably in 5 U/mL and 10 U/mL BoNT/A-treated group. **p<0.01, the concentration of NA decreased remarkably in 25 U/mL and 50 U/mL BoNT/A-treated group.
Abbreviations: BoNT/A, botulinum neurotoxin type A; NE, noradrenaline.
SNAP-25 in sympathetic neurons by immunofluorescence. As shown in Figure 8A, SNAP-25 was detected in SCGN.

After confirming the presence of SNAP-25 in sympathetic neurons, we examined protein levels by Western blot. After a high-dose treatment of BoNT/A (50 U/mL) for 24 h, cleaved SNAP-25 protein was detected. This result indicates that the functional role of BoNT/A was similar to cholinergic neurons. In contrast, cleaved SNAP-25 was not detected in the control group, and the 5 U/mL and 10 U/mL BoNT/A-treated groups (Figure 8B).

GM1, SV2C, and FGFR3 are located on sympathetic neurons

It has been previously shown that receptors like GM1, SV2C, and FGFR3 are the binding sites utilized by BoNT/A to enter the cholinergic neurons. In our study, we could see from Figure 9 that the neurons were immunopositive for GM1, SV2C, and FGFR3. The relationships between BoNT/A and these receptors need further study.

Discussion

In this study, we demonstrated the effect and possible mechanisms of BoNT/A on RP. Through the electrical stimulation-induced cremaster arteriole vasoconstriction model, we found that BoNT/A dose-dependently restrained the vasoconstriction of arteriole. The effect was similarly observed with prazosin, an α1-andrenoceptor antagonist. We also studied the impact of BoNT/A on sympathetic neurons, including the release of NE and the vesicle cycle in primary cultured superior cervical sympathetic neurons.
The BoNT/A inhibition effect may be mechanistically related to the cleavage of SNAP-25 which is also observed on cholinergic nerves. Moreover, the receptors involved in BoNT/A transportation were also detected in our cell model.

In the cremaster arteriole vasoconstriction model, we investigated and compared the role of BoNT/A in combination with endothelin receptor antagonist BQ-123, α1 adrenoceptor antagonist prazosin, and α2 adrenoceptor antagonist Yohimbine. We found that BoNT/A, prazosin, and BQ-123 have an effect on decreasing the arteriole diameter constriction rate. However, no effect was seen with Yohimbine treatment, which was similar to Stone et al’s report, indicating that BoNT/A application, in a dose-dependent manner, resulted in significant vasodilation of observed cremaster arterioles. In our study, we also found that the effects of prazosin and BoNT/A were also equivalent. Pretreatment with BoNT/A followed by BQ-123 treatment had a synergistic effect on arteriole vasoconstriction, while no beneficial result was observed from prazosin and Yohimbine, suggesting that BoNT/A can effectively abolish arteriole vasoconstriction by the “prazosin way”, and the endothelin-A receptor antagonist can enhance the role of BoNT/A, indicating BoNT/A might abolish arteriole vasoconstriction through the α1 adrenoceptor way.

Our results showed that the sympathetic adrenoceptors α1 and α2A were coexpressed on rat cremaster arteriole. However, α2B and α2C adrenoceptors were not detected by immunofluorescence. As reported in previous studies, α-adrenoceptors were subclassified into α1 and α2 subcategories. α1 adrenoceptors were predominately distributed on the postsynaptic membrane, while α2 receptors can be divided into A, B, and C subtypes distributed on both presynaptic and postsynaptic membranes. The lower expression of α2 adrenoceptors can perhaps explain the absence of Yohimbine effect.

Our findings suggested that BoNT/A might inhibit sympathetic nerves to mediate vasodilation. To further elaborate the impact of BoNT/A on sympathetic neurons we measured the vesicle cycle and the release of NE. Shone and Melling found that the release of NE decreased by 20% within 4 days when compared to the control group which decreased by 60%–65% by day 8 in PC12 cells. However, the PC12 cell model, which has sympathetic neuronal property, is differentiated from a rat adrenal pheochromocytoma clonal cell line by nerve growth factor (NGF). These cells cannot fully reflect the characteristics of sympathetic neurons. Therefore, in this study, primary cultures of neonatal rat superior cervical sympathetic ganglion neurons were established to further verify the reliability of previous results.

The vesicle cycle completion was measured by endocytosis and exocytosis, detected by FM1-43, which has been widely used in vesicle research. In our experiments, we found that the decrease of FM1-43 intensity was delayed in the presence of BoNT/A, indicating that the
vesicle cycle of sympathetic neurons could be inhibited by BoNT/A. However, this finding could not address whether the release of NE was affected. In an earlier study, Habermann et al. found that BoNT/A could inhibit the release of NE in fetal rat brain stem neurons. Our results showed a significant decrease of the NE concentration after BoNT/A intervention, especially in high concentrations of BoNT/A (50 U/mL), suggesting that the release of NE is dose-dependently blocked by BoNT/A, through inhibition of the vesicle cycle.

Studies on motor neurons have demonstrated that BoNT/A could inhibit formation of the SNARE complex and thereby block the quantization release of Ach, causing chemical denervation of the motor end plates. In this study, we found that the inhibitory effect of BoNT/A on NE release in sympathetic neurons might be related to SNAP-25 as well. However, cleaved SNAP-25 was only detected under 50 U/mL BoNT/A treatment after 24 h. In a previous study, our team had found that BoNT/As produced by different countries retain distinct potencies and various durations of effect after intramuscular administration. In other studies, natural BoNT/A which contained neither chelating protein nor stabilizer was used to explore the mechanism of BoNT/A in influencing motor neurons. The commercial one we used might influence the efficiency of toxin when compared to the purified one used in other studies. What is more, a different target protein might exist. Besides, BoNT/A might also function through other SNARE complex-dependent pathways in neurons and nonneuronal cells.

Until recently, some studies indicated that BoNT/A could combine with specific receptors located on the presynaptic membrane of motor neurons in a double-receptor model. The binding of BoNT/A with ganglioside launches the initial link step. It then combines with vesical transmembrane protein SV2 which has three isoforms, SV2A, SV2B, and SV2C. SV2C is believed to be the main receptor involved in BoNT/A binding in vitro. In addition, receptor FGFR3 is also involved. In our study, we were able to visualize the existence of ganglioside GM1, SV2C, and FGFR3 on the sympathetic neurons. However, the specific connection mode between BoNT/A and these three receptors is still under investigation.

**Conclusion**

Our study showed that BoNT/A can inhibit arteriole vasoconstriction in a dose-dependent manner by cleaving SNAP-25 in sympathetic neurons. This action inhibited vesicle fusion with the presynaptic membrane and blocked the release of NE. Through the study of the mechanism of BoNT/A affecting the sympathetic pathway in the treatment of Raynaud’s syndrome, this research provides a theoretical basis for the treatment of small vessel diseases caused by sympathetic dysfunction.

**Acknowledgments**

The work was supported by the National Natural Science Foundation of China (81500970 and 81470582), Shanghai Education Development Foundation and Shanghai Municipal Education Commission (14SG21), Priority of Shanghai Key Discipline of Medicine (2017ZZ0020), Shanghai Municipal Medical and Health Excellent Academic Leaders Training Program (2017BR029), and Shanghai Putuo District High Level Talents Scientific Research Innovation Project (2014-A-21).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**